Table 2

Metabolite ratios, white/grey matter ratios, and CSF to intracranial volume ratios for the five patients. Means (SD) from the seronegative high risk control group are also given. Time = Time relative to the commencement of antiretroviral therapy

	Time (weeks)	NA/(NA+Cho+Cr)	NA/Cr	NA/Cho	Cho/Cr	C_wg	CSF/ICV	HADC status^2-150
Patient 1	−7.6	0.42	1.72	1.26	1.36	1.02	0.15	–
	8.7	0.54	2.29	2.39	0.96	1.02	0.17	Improvement
	20.1	0.40	1.48	1.23	1.20	0.93	0.18	Deterioration

Patient 2	0.0	0.31	1.00	0.81	1.23	1.11	0.18	–
	3.8	0.47	1.96	1.68	1.17	1.08	0.22	Improvement
	15.2	0.41	1.72	1.19	1.44	1.13	0.23	Deterioration

Patient 3	−2.0	0.45	1.78	1.52	1.17	1.00	0.18	–
	−0.8	0.46	1.64	1.71	0.96	1.03	0.19	–
	13.2	0.52	2.16	2.16	1.00	0.89	0.24	Improvement

Patient 4	−0.3	0.55	2.30	2.56	0.90	1.34	0.12	–
	6.7	0.51	2.42	1.77	1.37	1.45	0.13	Improvement

Patient 5	−0.1	0.44	1.59	1.52	1.05	0.93	0.22	–
	4.7	0.51	2.20	1.94	1.13	0.94	0.26	No change^2-151

Controls (n=17) (mean (SD))	—	0.54 (0.04)	2.31 (0.49)	2.58 (0.68)	0.94 (0.27)	0.93 (0.05)	0.13 (0.03)	–

↵2-150 Degree of HADC (HIV associated dementia complex) relative to that at the time of the initial scan.
↵2-151 Patient improved clinically after the addition of lamivudine (3TC, GlaxoWellcome PLC, Beckenham, UK) to treatment regimen 4.7 weeks after the final scan.